Deferiprone promotes remyelination in MSDeferiprone promoted remyelination and functional recovery through enhancement of oligodendrogenesis in experimental demyelination animal model.
DFP's benefits extend beyond iron treatment.
We explored the effects of deferiprone (DFP), a medication known for its ability to chelate iron, on remyelination in a model of multiple sclerosis (MS). Focal demyelination was induced in the optic nerve of mice, and DFP was administered starting a week later to see if it could boost myelin repair.
Our observations revealed that DFP does more than just manage iron levels; it appears to significantly enhance the process of remyelination. We noted a decrease in the g-ratio and an increase in myelin thickness, hints that DFP is promoting the regeneration of myelin sheaths that protect nerve fibers. Furthermore, DFP also encouraged the growth of oligodendrocytes, which are crucial for myelin production, while reducing gliosis, an inflammatory response that can impede recovery.
The outcomes were impressive not just at a cellular level but also functionally. Mice treated with DFP showed notable recovery in their motor and sensory functions through various tests. Although we are still unraveling the precise mechanisms behind these improvements, our findings suggest that with further research, DFP could be a promising candidate for MS treatment focused on enhancing remyelination.
Read More